Analysis of data from the SECURE-IBD registry suggests anti-TNF antagonist and thiopurine combination therapy is associated with a significantly increased risk of hospitalization or death aOR 1.8 (95% CI 1.26–2.62) but not severe COVID-19 infection. Here, TNF is linked to inflammatory bowel disease.